Linked Life Data

19022778

Source:http://linkedlifedata.com/resource/pubmed/id/19022778

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2009-1-14
pubmed:abstractText
Resistant bacteria have renewed our interest in the aminoglycoside drugs. Evidence on the efficiency of aminoglycosides in their different clinical uses is available from numerous randomized controlled trials and has been accrued and examined in recent systematic reviews and meta-analyses. Their results show that aminoglycosides should not be added to broad-spectrum beta-lactams to achieve synergism in treating Gram-negative infections as combination does not improve efficacy and adds side effects. The evidence from randomized trials in humans does not support the use of aminoglycosides in staphylococcal or streptococcal endocarditis, and is lacking for endocarditis caused by enterococci. Aminoglycosides are efficacious and safe as single drugs for the treatment of pyelonephritis and sepsis of a urinary source, but their efficacy might be lower than that of beta-lactams in Gram-negative infections of other sources. In patients with no risk factors, aminoglycosides are as safe as beta-lactams regarding side effects. They probably induce less resistance. Pragmatic large trials are needed to answer open clinical questions on the use of aminoglycosides.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
1460-2091
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
63
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
246-51
pubmed:dateRevised
2009-4-16
pubmed:meshHeading
pubmed:year
2009
pubmed:articleTitle
Aminoglycoside drugs in clinical practice: an evidence-based approach.
pubmed:affiliation
Department of Medicine E, Beilinson Campus, Petah-Tiqva 49100, Israel. leibovic@post.tau.ac.il
pubmed:publicationType
Journal Article, Review